In the PREDI-LYNCH project, Tampere University leads a multinational clinical study where approximately 2,000 research subjects are randomised to undergo either the current colonoscopy screening or a liquid biopsy screening. Samples from the liquid biopsy group will be collected for all the sub-projects.
In addition to clinical work, the project will analyse large amounts of biological variables, such as genetics, gene expression, cell metabolism, and proteins, which will be used for new innovations.
The PREDI-LYNCH project aims for a rapid implementation of new screening methods across Europe. At the same time, it seeks to ensure that the solutions are compatible with different healthcare systems and societal values.
Funding
Partners
Consortium consists of 28 organisations from 16 European countries.